Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Devices
Q1 2026
Published: Aug 13, 2025
Earnings Highlights
EPS of $-1.07 decreased by 664.3% from previous year
Net income of -3.34M
"N/A" - N/A
Autonomix Medical Inc Common Stock (AMIX) QQ1 2026 Results – Development-stage Medical Device Company Advances Peripheral Nervous System Sensing Platform
Executive Summary
Autonomix Medical Inc (AMIX) reported QQ1 2026 results with no disclosed revenue for the quarter and a substantial operating loss driven by ongoing R&D and administrative investments. The quarter ended 2025-06-30 shows operating expenses of $3.421 million (R&D $1.593 million; G&A $1.829 million) and an EBITDA of -$3.334 million, resulting in an operating loss of -$3.421 million and a net loss of -$3.337 million (EPS -$1.07). While the company is not yet generating revenue, cash from financing activities partially offset cash burn, leaving a modest net cash decrease of $0.547 million for the period and a cash balance of $8.589 million at quarter-end.
From a balance sheet perspective, total assets stood at $8.997 million and total liabilities at $1.965 million, with stockholders’ equity of $7.032 million. Negative retained earnings of -$53.716 million reflect cumulative losses, offset by accumulated other equity components totaling $60.744 million, suggesting continued external funding support typical of a development-stage device company. No debt is reported, and the company remains funded primarily through equity and other comprehensive equity instruments.
Key takeaway: AMIX remains in the pre-commercial phase, exhibiting a meaningful cash burn tied to platform development. The near-term equity-market and clinical/validation milestones will be critical to extending the cash runway and unlocking potential partnerships or licensing opportunities. Absent revenue generation or a clear monetization event, upside hinges on successful data readouts, strategic collaborations, and continued access to capital.
Key Performance Indicators
Operating Income
-3.42M
QoQ: -5.20% | YoY:-24.26%
Net Income
-3.34M
QoQ: -4.58% | YoY:-23.64%
EPS
-1.07
QoQ: 40.88% | YoY:-664.29%
Revenue Trend
Margin Analysis
Key Insights
Net cash provided by operating activities: -$2.604 million
Net cash provided by financing activities: +$2.057 million
Net change in cash: -$0.547 million
Cash at end of period: $8.589 million
Free cash flow: -$2.604 million
Financial Highlights
Revenue: Not disclosed for QQ1 2026; no reported quarterly revenue in the data set.
Gross Profit: -$3,000; Gross Margin not provided (data suggests negative gross profit in the quarter).
Cash Flow and Liquidity:
- Net cash provided by operating activities: -$2.604 million
- Net cash provided by financing activities: +$2.057 million
- Net change in cash: -$0.547 million
- Cash at end of period: $8.589 million
- Free cash flow: -$2.604 million
Balance Sheet Highlights:
- Total assets: $8.997 million
- Total current assets: $8.978 million (cash and cash equivalents: $8.589 million)
- Total current liabilities: $1.965 million
- Total liabilities: $1.965 million
- Total stockholders’ equity: $7.032 million
- Retained earnings: -$53.716 million
- Common stock: $4.000 thousand
- Other comprehensive/equity components: $60.744 million (offsetting negative retained earnings)
Valuation/Peers:
- Peer ratios: No peers found for stock AMIX in the provided data; sector-wide comparisons would rely on industry norms for pre-revenue medical device companies (high R&D intensity, operating losses in early years, dependence on external funding).
Income Statement
Metric
Value
YoY Change
QoQ Change
Gross Profit
-3.00K
93.02%
N/A
Operating Income
-3.42M
-24.26%
-5.20%
Net Income
-3.34M
-23.64%
-4.58%
EPS
-1.07
-664.29%
40.88%
Key Financial Ratios
Net Income vs. Revenue
Expense Breakdown
Management Commentary
Transcript highlights are not available in the provided data. No earnings-call quotes are included. If a transcript becomes available, key themes to extract would include: (1) strategy and pipeline priorities for the peripheral nervous system sensing platform; (2) anticipated data readouts, clinical milestones, and regulatory timelines; (3) cost-control measures or efficiency initiatives; (4) potential strategic partnerships, licensing opportunities, or manufacturing milestones. Once available, these quotes should be grouped by theme with context on significance (e.g., milestone achievement, partnership discussions, or funding needs).
N/A
— N/A
N/A
— N/A
Forward Guidance
No explicit forward guidance was disclosed in the QQ1 2026 filing. Given the company’s development-stage status, management commentary (when available) would likely emphasize ongoing R&D investments, anticipated product or clinical milestones, and the potential for partnerships or licensing to de-risk commercialization. Investors should monitor: (a) upcoming clinical or preclinical data readouts and regulatory milestones, (b) any announced strategic collaborations or licensing discussions, and (c) capital-raising plans or financing terms that could affect share count and dilution. The absence of revenue guidance is typical for a pre-commercial platform; thus, guidance hinges on milestone-driven value realization.
Competitive Position
Company
Gross Margin
Operating Margin
Return on Equity
P/E Ratio
Gross Profit Margin
Operating Profit Margin
Return on Equity
P/E Ratio Comparison
Investment Outlook
AMIX presents a high-risk, high-reward profile typical of a pre-commercial medical device developer. The near-term investment case rests on the potential for upcoming data readouts, regulatory progress, and the ability to secure strategic partnerships or licensing deals that could translate the platform into revenue. While the current cash position and lack of debt provide a degree of financial flexibility, the company continues to run substantial losses and has no revenue visibility in the QQ1 2026 period. Investors should closely monitor milestones that could de-risk commercialization (data readouts, feasibility studies, or pilot partnerships) and any announced financing plans that could affect share count. If the company demonstrates meaningful clinical or regulatory progress and secures favorable collaborations, the long-term upside could be material; otherwise, downside risks center on continued pre-revenue status and capital-raising needs.
Key Investment Factors
Growth Potential
AMIX operates a catheter-based microchip-enabled sensing platform aimed at differentiating peripheral neural signals. If the platform demonstrates clinically meaningful data and favorable safety/effectiveness signals, potential growth drivers include licensing deals, collaboration agreements with larger medtech players, and eventual commercialization in targeted neuromodulation indications.
Profitability Risk
Key risks include ongoing lack of revenue, high R&D and G&A burn, reliance on external financing, regulatory and clinical development risk, potential equity dilution to fund operations, and competition from established or emerging neuromodulation platforms. The absence of near-term revenue increases the sensitivity of the stock to financing conditions and milestone-driven milestones.
Financial Position
The company maintains a cash balance of $8.589 million with no debt, supported by accumulated other equity totaling $60.744 million, offsetting negative retained earnings of -$53.716 million. While liquidity is acceptable in the near term, the lack of earnings and persistent losses imply continued dependence on equity financing to fund operations and platform development.
SWOT Analysis
Strengths
Liquidity buffer with $8.589M cash and no debt provides runway for R&D and platform development.
Developing catheter-based microchip-enabled sensing platform targeting peripheral neural signals, a potentially differentiating technology in a high-need area.
Capital structure supported by accumulated other equity (approx. $60.744M) offsetting negative retained earnings, indicating external investor support.
Weaknesses
No reported revenue for QQ1 2026; business is pre-commercial and loss-making.
High ongoing R&D and G&A burn ($1.593M and $1.829M respectively) driving operating loss.
Dependency on external funding and potential equity dilution to sustain operations.
Opportunities
Potential data readouts or clinical validation could unlock partnerships, licensing, or licensing revenue.
Opportunity to license or co-develop platform with larger medtech companies; possible expansion into additional indications tied to peripheral nervous system disorders.
Threats
Regulatory and clinical development risk that could delay commercialization.
Competition from established neuromodulation and diagnostic platforms; market adoption risk in a cautious medical device environment.
Financing volatility and dilution risk if additional capital is needed to fund ongoing R&D and ops.
Autonomix Medical Inc. (AMIX) QQ1 2025 Results: Development-Stage Medical Device Platform Faces No Revenue Yet with Dry Powder for Pipeline Advancemen...